Portola Pharmaceuticals has initiated a Phase I/II study of PRT2070, a novel, oral, dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor. The compound is being developed for patients with genetically-defined hematologic cancers, as well as for patients who have failed therapy due to relapse or acquired mutations. PRT2070’s dual mechanism of action targets two validated pathways for tumor survival and proliferation. The open-label, multicenter, Phase I/II proof-of-concept stu...